The present disclosure relates generally to stents, and, in particular, relates to stents having particular nodes with a non-constant radius of curvature.
Stents are widely used for numerous applications where the stent is placed in the lumen of a patient and expanded. Such stents may be used in coronary or other vasculature, as well as other body lumens.
Commonly, stents are cylindrical members. The stents expand from reduced diameters to enlarged diameters. Stents may either be self-expanding or balloon-expandable. Self-expanding stents are generally inserted into vasculature via a delivery device; the removal of the delivery device causes the stent to radially expand. Balloon-expandable stents are placed on a balloon catheter with the stent in the reduced-diameter state. So placed, the stent is advanced on the catheter to a placement site. At the site, the balloon is inflated to expand the stent to the enlarged diameter. The balloon is deflated and removed, leaving the enlarged diameter stent in place. So used, such stents are used to substantially retain or expand diameters of occluded sites within a patient's vasculature or other lumen.
Examples of stents are numerous. For example, U.S. Pat. No. 5,449,373 to Pinchasik et al. teaches a stent with at least two rigid segments joined by a flexible connector. U.S. Pat. No. 5,695,516 to Fischell teaches a stent with a cell having a butterfly shape when the stent is in a reduced-diameter state. Upon expansion of the stent, the cell assumes a hexagonal shape.
When stents are placed in certain parts of the body, it may be desirable for the stent to be both strong and flexible. For example, when a stent is placed within a patient's vasculature at or near a patient's joint (e.g., hip, knee, elbow, etc.), the stent may be bent often and may be subject to a relatively large amount of mechanical strain. Thus, a stent that is both flexible and strong may be desirable for use in these and other instances.
The present disclosure relates to a stent comprising a stent body and a plurality of cells. Each cell includes two structural members extending in an undulating pattern. Each structural member includes a plurality of cell segments defining a plurality of nodes therebetween. At least one node includes a non-constant radius of curvature.
In disclosed embodiments, the at least one node that includes a non-constant radius of curvature includes at least two distinct radii of curvature.
In disclosed embodiments, a first node includes a radius of curvature of between about 0.0015 inches and about 0.0030 inches. Here, it is disclosed that a second node includes a radius of curvature of between about 0.0050 inches and about 0.0150 inches. Here, it is disclosed that a third node includes a radius of curvature of between about 0.0015 inches and about 0.0030 inches. Here, it is disclosed that a fourth node includes a radius of curvature of between about 0.0050 inches and about 0.0150 inches.
The present disclosure also relates to a stent comprising a stent body defining a length and comprising a plurality of cells. Each cell comprises two structural members extending in an undulating pattern. Each structural member comprises a plurality of cell segments defining a plurality of peaks and valleys therebetween. A first segment and a second segment define a first peak. The second segment and a third segment define a first valley. The third segment and a fourth segment define a second peak. The fourth segment and a fifth segment define a second valley. The fifth segment and a sixth segment define a third peak. At least one peak or valley includes a non-constant radius of curvature.
In disclosed embodiments, each of the first peak and the first valley include a non-constant radius of curvature.
In disclosed embodiments, the at least one peak or valley that includes a non-constant radius of curvature includes at least two distinct radii of curvature.
In disclosed embodiments, the each of the first peak and the first valley include at least two distinct radii of curvature.
In disclosed embodiments, the first peak includes a radius of curvature of between about 0.0015 inches and about 0.0030 inches. Here, it is disclosed that the second peak includes a radius of curvature of between about 0.0050 inches and about 0.0150 inches. Here, it is disclosed that the first valley includes a radius of curvature of between about 0.0015 inches and about 0.0030 inches. Here, it is disclosed that the second valley includes a radius of curvature of between about 0.0050 inches and about 0.0150 inches.
In disclosed embodiments, the second peak, the third peak and the second valley each include a single radius of curvature. Here, it is disclosed that the radius of curvature is between about 0.0001 inches and about 0.0020 inches.
In disclosed embodiments, the each structural member includes a seventh segment and an eighth segment. The sixth segment and the seventh segment define a third valley, and the seventh segment and the eighth segment define a fourth peak. Here, it is disclosed that the second peak, the third peak, the fourth peak, the second valley, and the third valley each include a single radius of curvature, and the radius of curvature is between about 0.0001 inches and about 0.0020 inches.
The present disclosure also relates to a stent comprising a stent body defining a length and comprising a plurality of cells. Each cell comprises two structural members extending in an undulating pattern. Each structural member comprising a plurality of cell segments defining a plurality of nodes therebetween. The radius of curvature of a first node is different from a radius of curvature of a second node. At least one node includes a non-constant radius of curvature.
In disclosed embodiments, the at least one node that includes a non-constant radius of curvature is a third node.
Embodiments of the present disclosure will be readily appreciated by reference to the drawings wherein:
In the following description, the terms “proximal” and “distal” as used herein refer to a direction or a position along a longitudinal axis of a catheter or medical instrument. The “proximal” or “trailing” end of the instrument is generally the segment of the instrument that is closest to the clinician or to the entrance site into a body. The “distal” or “leading” end of the instrument is generally the segment of the instrument placed farthest into a body lumen from the entrance site. Additionally, the term “preloaded” relates to the configuration of the stent prior to the stent being loaded into a catheter, and the term “predeployed” relates to the configuration of the stent while the stent is compacted into the catheter.
The stent of the present disclosure has particular application in the vasculature of a patient where it is subject to a relatively high amount of strain and movement. For example, the disclosed stent may be suitable for use within the vasculature of a patient's hip area, e.g., to help reduce problems associated with a deep vein thrombosis (DVT). However, the disclosed stent may be used in any interventional, diagnostic, and/or therapeutic procedure. The stent may be a component of an apparatus or system used in conjunction with any of the above applications.
The various embodiments of the disclosure will now be described in connection with the drawings. It should be understood that for purposes of better describing the disclosure, the drawings may not be to scale. Further, some of the figures may include enlarged or distorted portions for the purpose of showing features that would not otherwise be apparent.
With initial reference to
With continued reference to
Referring to
With particular reference to
In the illustrated embodiment, segments 141-148 extend generally longitudinally along stent 100. The term “generally longitudinally” will be understood to mean that segments 141-148 are closer to a parallel relationship relative to the axis A-A of stent 100 (e.g.,
Each node is a generally semi-circular arcuate segment including at least one radius of curvature, a length “LS” (along axis A-A), and a width “WS” (perpendicular to axis A-A) (see
With reference to
While
Additionally, while particular nodes (i.e., peak 150 and valley 160) are each shown having a non-constant radius of curvature, it is envisioned and within the scope of the present disclosure that any combination of nodes 150, 152, 154, 156, 160, 162 and 164 may include a non-constant radius of curvature. It is further disclosed that any peak and any valley of each cell 120 may have any of the disclosed constant or non-constant radii of curvature.
The present disclosure also contemplates embodiments where nodes 152, 162, 156 and the valley created by segments 141 and 148 each include a non-constant radius of curvature. Here, it is envisioned that each of the non-constant radius of curvatures are equal to each other. In these embodiments, it is further envisioned that nodes 154 and 164 include a constant radius, which are equal to each other.
As discussed hereinabove, the disclosed stent 100 includes cells 120 having multiple nodes, wherein at least one node has a non-constant radius of curvature. It is envisioned that these features help improve the life and/or durability of the disclosed stent 100. For example, the mechanical strains undergone by stent 100 when stent 100 is within a patient's vasculature (e.g., within a region subject to repeated joint flexure) results in a more balanced distribution of strains versus a typical stent where each node has a constant and/or equal radius, for example. A combination of finite element analysis, durability testing, fatigue testing, and repeating bending load testing may be performed to help determine the desired ranges of dimensions for each node and to tune the desired performance of a given stent 100. For example, to help balance the strains undergone by stent, the portions of a radius of the node that experiences the highest strains during testing (e.g., finite element analysis, durability testing, fatigue testing, and/or repeating bending load testing) is increased. If/when a different node experiences the highest strains during a subsequent test, a portion of the radius of that node is increased. This testing process is repeated until the strength and/or size of the compacted diameter become unacceptable for its desired application, and/or until additional increases in node radius provides negligible additional improvement in strength or durability.
When stent 100 is compacted into the catheter (i.e., its predeployed configuration), the diameter of stent 100 is reduced as compared to when stent 100 has not yet been loaded into the catheter (i.e., its preloaded configuration). This associated reduction in stent circumference is accommodated by reduction in the angles between segments which results in an increase in bending strain (e.g., especially adjacent nodes). As the cell is deformed (e.g., when stent 100 is loaded into catheter, or when the delivery system is navigating through the vasculature to the treatment site), especially during bending or axial loading, certain angles between adjacent segments increase or decrease more than others due to the lack of symmetry inherent in most flexible stent designs. As a result, there is a greater amount of strain in the nodes that connect those adjacent segments. The amount of strain concentrated near the nodes can be calculated using finite element analysis, for example.
The maximum strain in a deformed stent is called the peak strain. The peak strain typically occurs in a single segment in the vicinity of a node although it may occur elsewhere in the stent depending on the stent design. Predominant strains in stents may be tensile (usually defined as positive) or compressive (usually defined as negative). Strains can be categorized as being of two kinds: normal strains and shear strains. Normal strains can be positive (e.g., tensile) or negative (e.g., compressive). There are positive and negative shear strains as well, but in this case the sign convention is arbitrary, and physically there is no real difference between positive and negative shear strains. Normal strains, which are also referred to as principal strains, are generally the basis for strain analysis and durability analysis of stents.
High tensile strains may cause cracks to initiate and propagate through the stent, leading to reduced fatigue life and stent fracture (i.e., failure mode). Compressive strains do not tend to cause cracks, and so generally do not cause reduced stent life unless the magnitude of the strain is extraordinary. Some portions of a deformed stent may be highly strained during use while other portions may not be strained at all. A deformed stent can be thought of as a collection of tiny volumetric regions, each region having a strain level; collectively, the strain levels of the regions range from a maximum negative value to a maximum positive value. For a stent in service in the body, if stent strains are maintained below the endurance limit of the stent material then high fatigue life may be expected assuming the stent material has undergone proper materials processing and surface finishing. However, if a stent in service in the body suffers stent strains above the endurance limit of the stent material then high fatigue life cannot be expected regardless of stent material processing and surface finishing.
Commonly, stents are designed such that the strain in the stent remains at a low level under pulsatile loading conditions, i.e. under oscillating circumferential compressive strains. However, it has been determined that stents implanted in other locations, for example within a patient's vasculature at or near a patient's joint, can subject a stent to larger amounts of strain than previously predicted.
Bending and any associated elongation of stent 100 results in concentration of tensile strains at and within particular nodes thereby exposing the segments near or adjacent the nodes, and the nodes themselves, to lower fatigue life. Concentration of compressive strains in other nodes permit the segments near or adjacent those nodes to sustain higher fatigue life. As such, balancing the strains experienced by the stent 100 increases the overall fatigue life of stent 100. Balancing the strain may involve changing the design of the stent 100 such that the nodes that are otherwise exposed to higher levels of tensile strains have a way to distribute that strain to help improve the fatigue life of the particular node and adjacent segments, and thus, help improve the fatigue life of the entire stent 100.
The design of stent 100 of the present disclosure helps balance the strain by providing nodes with a non-constant radius. As the strain is concentrated in regions where the radius of curvature is the smallest, it follows that by increasing the radius, the peak strain is reduced. The nodes having non-constant radii have a larger radius of curvature through the parts of the node that undergo the larger amount of strain, and a smaller radius of curvature through the parts of the node that undergo the smaller amount of strain. Thus, the portion of the node with the larger radius lowers the peak strain associated therewith, and which thus improves fatigue life (i.e., helps prevent the stent from breaking). Further, the nodes of stent 100 that include this non-constant radii of curvature may be the nodes that undergo the highest peak strains during various testing procedures. Therefore, the overall life and performance of the stent is improved.
However, while altering the radii of various nodes may improve certain aspects of the stent design, such changing of radii may affect the strength of at least part of the stent. More particularly, stent 100 may be compacted to a relatively small diameter in order to enable stent 100 to fit into a delivery system that travels through a patient's vasculature. Generally, as the node radius increases and the segment widths remain constant, the minimum compaction diameter increases in proportion to the increase in radius. If the required compaction diameter is desired to be a fixed amount, then as the node radius is increased, the segment widths would have to decrease. This decrease in segment width may lead to a decrease in stent strength. Thus, for each stent design and desired application, it is possible to tune the overall stent design to ensure the durability benefits outweigh the loss of strength or an increase in compaction diameter due to increasing the node radius. By way of a non-limiting example, for venous stents (as compared to arterial stents) the diameter of the delivery system may be less critical for two reasons: 1) veins generally have larger diameters than arteries; and 2) blood pressure is lower in veins versus arteries, so the size of an access hole made to get the delivery device into a vein may be less critical, as once the procedure is complete, it is easier to stop the bleeding from a hole in a vein than in an artery. Thus, the design of a stent can be tuned for a venous application by considering the desired strength of the stent, the desired durability, and the desired size of its compacted diameter, along with the interplay between these criteria.
It is further envisioned that in addition to stent 100 having at least node with a non-constant radius of curvature, at least two nodes of stent 100 include different radii of curvature from one another. In certain situations, a stent having a combination of nodes with different radii of curvature and with non-constant radii of curvature may further augment the balanced distribution of forces. Further details of stents having nodes with different radii of curvature from one another is disclosed in U.S. application Ser. No. 13/834,840, filed concurrently with the present application on Mar. 15, 2013, and granted on Nov. 10, 2015 as U.S. Pat. No. 9,180,031, the entirety of which is hereby incorporated by reference herein.
In disclosed embodiments, the width “WS” of each node is between about 0.0240 inches and about 0.0265 inches (e.g., equal to about 0.0250 inches). In disclosed embodiments, the length “LS” of each node is between about 0.0130 inches and about 0.0170 inches (e.g., equal to about 0.0155 inches). In disclosed embodiments, the width “WCP” of connecting portions 130 (see
It is envisioned that the each cell 120 and the entire stent 100 can be of any reasonable dimension for the intended purpose of use within a patient's vasculature. Likewise, the total number of cells 120 can be of any reasonable value. Further, as shown in
In disclosed embodiments, the inside diameter of a preloaded stent 100 (i.e., prior to insertion into a catheter) is between about 0.5000 inches and about 0.6000 inches, and the inside diameter of a predeployed stent 100 (i.e., compacted within a catheter) is between about 0.0500 inches and about 0.0600 inches.
In use, stent 100 is advanced to a site in a bodily lumen. Stent 100 is then expanded at the site. Stent 100 may be expanded through any conventional means. For example, stent 100 may be placed on the balloon tip of a catheter. Here, the balloon is expanded at the site to generate radial forces on the interior of stent 100. The radial forces urge stent 100 to radially expand, e.g., without appreciable longitudinal expansion or contraction. Plastic deformation of the material of stent 100 (e.g., stainless steel) results in stent 100 retaining the expanded shape following subsequent deflation of the balloon.
Additionally, stent 100 can be mounted on a delivery catheter. As is conventionally known in the art, stent 100 can be held in a compressed orientation on the delivery catheter by a retractable sheath. As is also known in the art, the delivery catheter can be used to advance stent 100 to a deployment location (e.g., a constricted region of a vessel). At the deployment site, the sheath is retracted thereby releasing stent 100. Once released, stent 100 self-expands to the deployed diameter. While an envisioned use for the features disclosed in the accompanying figures relates to that of a self-expanding stent, the features also have benefits when used with non-self-expanding stents (e.g., balloon expandable stents made of a material such as stainless steel).
To advance to a site, the axis A-A of stent 100 must bend to navigate through a curved lumen. Further, for placement at a curved site in a lumen, stent 100 must be sufficiently flexible to retain a curved shape following expansion and to bend as the lumen bends over time.
Numerous modifications are possible. For example stent 100 may be lined with either an inner or outer sleeve (such as polyester fabric or ePTFE) to facilitate tissue growth. Also, at least a portion of stent 100 may include or be coated with radiopaque coatings such as platinum, gold, tungsten or tantalum. In addition to materials previously discussed, stent 100 may be formed of other materials, including, without limitation, MP35N, tantalum, platinum, gold, Elgiloy and Phynox. Alternatively, the stent 100 may be formed of a super-elastic or shape memory material (e.g., nitinol).
While three cells 120 are shown in
When forming stent 100 from a shape memory metal such as nitinol, stent 100 can be laser cut from a nitinol tube. Thereafter, stent 100 can be subjected to a shape-setting process in which the cut tube is expanded on a mandrel and then heated. Multiple expansion and heating cycles can be used to shape-set stent 100 to the final expanded diameter. It is envisioned that the final expanded diameter is equal to the desired deployed diameter of stent 100. During expansion, it is envisioned that stent 100 is axially restrained such that the length of stent 100 does not change during expansion. It is further envisioned that the finished stent 100 has an austenite finish temperature less than body temperature. Here, at body temperature, stent 100 will self-expand to the desired deployed diameter due to the shape memory characteristic of the metal forming stent 100.
From the foregoing and with reference to the various figure drawings, those skilled in the art will appreciate that certain modifications can also be made to the present disclosure without departing from the scope of the same. It is not intended that the disclosure be limited to the embodiments shown in the accompanying figures, as it is intended that the disclosure be as broad in scope as the art will allow and that the specification be read likewise. Therefore, the above description should not be construed as limiting, but merely as exemplifications of particular embodiments. Those skilled in the art will envision other modifications within the scope and spirit of the claims appended hereto.
This application is a divisional of U.S. patent application Ser. No. 14/993,734, filed Jan. 12, 2016 and naming inventors Vogel et al., which is a continuation of U.S. patent application Ser. No. 13/834,713, filed Mar. 15, 2013 and naming inventors Vogel et al., now U.S. Pat. No. 9,259,335. The entire content of each of these applications is incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
4733665 | Palmaz | Mar 1988 | A |
5449373 | Pinchasik et al. | Sep 1995 | A |
5707386 | Schnepp-Pesch et al. | Jan 1998 | A |
5718713 | Frantzen | Feb 1998 | A |
5759192 | Saunders | Jun 1998 | A |
5843164 | Frantzen et al. | Dec 1998 | A |
5860999 | Schnepp-Pesch et al. | Jan 1999 | A |
5965516 | Boutique et al. | Oct 1999 | A |
6190406 | Duerig et al. | Feb 2001 | B1 |
6306141 | Jervis | Oct 2001 | B1 |
6348065 | Brown et al. | Feb 2002 | B1 |
6358274 | Thompson | Mar 2002 | B1 |
6558415 | Thompson | May 2003 | B2 |
6623518 | Thompson et al. | Sep 2003 | B2 |
6699278 | Fischell et al. | Mar 2004 | B2 |
6755856 | Flerens et al. | Jun 2004 | B2 |
6814746 | Thompson et al. | Nov 2004 | B2 |
6818014 | Brown et al. | Nov 2004 | B2 |
6863685 | Davila et al. | Mar 2005 | B2 |
6913619 | Brown et al. | Jul 2005 | B2 |
6962603 | Brown et al. | Nov 2005 | B1 |
6981986 | Brown et al. | Jan 2006 | B1 |
7147660 | Chobotov et al. | Dec 2006 | B2 |
7147661 | Chobotov et al. | Dec 2006 | B2 |
7316711 | Allen | Jan 2008 | B2 |
7329277 | Addonizio et al. | Feb 2008 | B2 |
7473275 | Marquez | Jan 2009 | B2 |
7625400 | Bowe et al. | Dec 2009 | B2 |
7655033 | Fearnot et al. | Feb 2010 | B2 |
7753948 | Roeder et al. | Jul 2010 | B2 |
7766954 | Chobotov et al. | Aug 2010 | B2 |
7993388 | Lee et al. | Aug 2011 | B2 |
8114149 | Fishcell et al. | Feb 2012 | B2 |
8167927 | Chobotov | May 2012 | B2 |
8187396 | Parker | May 2012 | B2 |
8211162 | Tischler et al. | Jul 2012 | B2 |
8236043 | Caro et al. | Aug 2012 | B2 |
8241346 | Chobotov | Aug 2012 | B2 |
8328864 | Niermann | Nov 2012 | B2 |
8382816 | Pollock et al. | Feb 2013 | B2 |
8658081 | Gale et al. | Feb 2014 | B2 |
9180031 | Vogel et al. | Nov 2015 | B2 |
9259335 | Vogel et al. | Feb 2016 | B2 |
9943425 | Vogel et al. | Apr 2018 | B2 |
20020007212 | Brown et al. | Jan 2002 | A1 |
20040093073 | Lowe et al. | May 2004 | A1 |
20040167635 | Yachia et al. | Aug 2004 | A1 |
20050096727 | Allen et al. | May 2005 | A1 |
20060015173 | Clifford | Jan 2006 | A1 |
20070100434 | Gregorich et al. | May 2007 | A1 |
20070239263 | Fliedner | Oct 2007 | A1 |
20080221661 | Bidne et al. | Sep 2008 | A1 |
20090105809 | Lee et al. | Apr 2009 | A1 |
20100137974 | Chouinard et al. | Jun 2010 | A1 |
20100262227 | Rangwala et al. | Oct 2010 | A1 |
20100312326 | Chuter et al. | Dec 2010 | A1 |
20110213455 | Obradovic et al. | Sep 2011 | A1 |
20120165920 | Meyer et al. | Jun 2012 | A1 |
20120226346 | Boismier et al. | Sep 2012 | A1 |
20130218260 | Schlun et al. | Aug 2013 | A1 |
20140128959 | Gale et al. | May 2014 | A1 |
20150105852 | Noffke et al. | Apr 2015 | A1 |
20180296376 | Vogel et al. | Oct 2018 | A1 |
Number | Date | Country |
---|---|---|
1479596 | Mar 2004 | CN |
101385669 | Mar 2009 | CN |
101516291 | Aug 2009 | CN |
100566681 | Dec 2009 | CN |
10144430 | Mar 2003 | DE |
1523959 | Apr 2005 | EP |
WO97025937 | Jul 1997 | WO |
WO 2002100298 | Dec 2002 | WO |
WO2003017870 | Mar 2003 | WO |
WO2004028571 | Apr 2004 | WO |
WO2007005800 | Jan 2007 | WO |
WO2007013102 | Feb 2007 | WO |
WO2008005535 | Jan 2008 | WO |
2012091770 | Jul 2012 | WO |
WO2012096716 | Jul 2012 | WO |
WO2012143731 | Oct 2012 | WO |
Entry |
---|
Response to Examination Report dated Feb. 22, 2018, from counterpart European Application No. 14709048.4, filed Jun. 25, 2018, 8 pp. |
Notice of Allowance from U.S. Appl. No. 14/878,600, dated Mar. 21, 2018, 8 pp. |
Decision on Appeal from U.S. Appl. No. 14/055,120, dated Feb. 19, 2019, 23 pp. |
Office Action from U.S. Appl. No. 14/055,120, dated May 16, 2019, 19 pp. |
Final Office Action from U.S. Appl. No. 14/055,120, dated Jul. 14, 2016, 16pp. |
First Office Action, and translation thereof, from counterpart Chinese Application No. 201480015518.0. dated Aug. 25, 2016. |
Notice of Appeal and Pre-Appeal Brief Request for Review from U.S. Appl. No. 14/055,120, filed Oct. 14, 2016, 7 pp. |
Second Office Action, and translation thereof, from counterpart Chinese Application No. 201480015518.0. dated Apr. 10, 2017, 10 pp. |
Examiners Answer from U.S. Appl. No. 14/055,120, dated May 5, 2017, 21 pp. |
Final Rejection from U.S. Appl. No. 14/878,600, dated May 12, 2017, 12 pp. |
Response to Examiner's Answer dated May 5, 2017, from U.S. Appl. No. 14/055,120, filed Jul. 5, 2017, 16 pp. |
Prosecution History from U.S. Appl. No. 14/055,120, dated May 8, 2015, through Jun. 8, 2016, 91 pp. |
U.S. Appl. No. 14/878,600 by Jeffrey H. Vogel et al., filed Oct. 8, 2015. |
Prosecution History from U.S. Appl. No. 13/834,840, dated Sep. 12, 2014 through Aug. 31, 2015, 63 pp. |
Prosecution History from U.S. Appl. No. 13/834,713, dated Mar. 12, 2015, through Dec. 16, 2015, 30 pp. |
Office Action from U.S. Appl. No. 14/878,600, dated Dec. 6, 2016, 10 pp. |
Response to Office Action dated Dec. 6, 2016, from U.S. Appl. No. 14/878,600, filed Mar. 6, 2017, 11 pp. |
Office Action from U.S. Appl. No. 14/055,120, dated Jun. 1, 2015 15pp. |
Final Office Action from U.S. Appl. No. 14/055,120, dated Oct. 16, 2015 13 pp. |
Notice of Allowance from U.S. Appl. No. 13/834,840, dated Apr. 3, 2015, 7pp. |
Final Office Action from U.S. Appl. No. 13/834,840, dated Jan. 16, 2015, 9 pp. |
Non-Final Office Action from U.S. Appl. No. 13/834,840, dated Sep. 12, 2014, 13pp. |
International Search Report for PCT Application Serial No. PCT/US2014/017095, dated Apr. 25, 2014, 4pgs. |
International Search Report for PCT Application Serial No. PCT/US2014/017102, dated Jun. 16, 2014, 3pgs. |
Office Action from U.S. Appl. No. 16/016,126, dated Jan. 13, 2020, 10 pp. |
Response to Office Action dated Jan. 13, 2020, from U.S. Appl. No. 16/016,126, filed Apr. 9, 2020, 12 pp. |
Notice of Allowance from U.S. Appl. No. 13/834,840, dated Jul. 10, 2015, 7 pp. |
Prosecution History from U.S. Appl. No. 14/055,120, dated Mar. 10, 2015 through Jan. 29, 2020, 263 pp. |
Prosecution History from U.S. Appl. No. 14/878,600, dated Oct. 12, 2015 through May 16, 2018, 89 pp. |
Prosecution History from U.S. Appl. No. 14/993,734, dated Apr. 5, 2016 through Dec. 13, 2017, 42 pp. |
Examination Report from counterpart European Application No. 14709048.4, dated Feb. 22, 2018, 6 pp. |
Examination Report from counterpart European Application No. 14709048.4, dated Dec. 5, 2018, 4 pp. |
Response to Examination Report dated Dec. 5, 2018, from counterpart European Application No. 14709048.4, filed Apr. 3, 2019, 10 pp. |
Notice of Intent to Grant and Text Intended to Grant from counterpart European Application No. 14709048.4, dated Mar. 25, 2020, 31 pp. |
Interational Preliminary Report on Patentability and Written Opinion of International Application No. PCT/US2014/017102, dated Sep. 15, 2015, 11 pp. |
International Search Report from International Application No. PCT/US2014/017102, dated Sep. 25, 2014, 3 pp. |
Written Opinion, and machine translation thereof, from counterpart Korean Application No. 10-2015-7028512, dated Apr. 24, 2020, 14 pp. |
Notification to Grant, and translation thereof, from counterpart Chinese Application No. 201480015518.0, dated Sep. 13, 2017, 3 pp. |
Response to Israel Office Action dated Feb. 6, 2019, from counterpart Israel Application No. 240782, filed May 20, 2019, 10 pp. |
Final Office Action from U.S. Appl. No. 16/016,126, dated Jun. 18, 2020, 9 pp. |
Number | Date | Country | |
---|---|---|---|
20180200090 A1 | Jul 2018 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14993734 | Jan 2016 | US |
Child | 15918912 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13834713 | Mar 2013 | US |
Child | 14993734 | US |